BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32161058)

  • 1. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
    Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
    Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
    Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
    Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers.
    Delcoigne B; Kopp TI; Arkema EV; Hellgren K; Provan SA; Relas H; Aaltonen K; Trokovic N; Gudbjornsson B; Grondal G; Klami Kristianslund E; Lindhardsen J; Dreyer L; Askling J
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36854568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
    Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
    Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study.
    Hellgren K; Ballegaard C; Delcoigne B; Cordtz R; Nordström D; Aaltonen K; Gudbjornsson B; Love TJ; Aarrestad Provan S; Sexton J; Zobbe K; Kristensen LE; Askling J; Dreyer L
    Rheumatology (Oxford); 2021 Aug; 60(8):3656-3668. PubMed ID: 33401297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
    Christensen IE; Lillegraven S; Mielnik P; Bakland G; Loli L; Sexton J; Uhlig T; Kvien TK; Provan SA
    Ann Rheum Dis; 2022 Mar; 81(3):398-401. PubMed ID: 34625404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
    Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
    Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study.
    Rotar Z; Svetina P; Tomsic M; Hočevar A; Prapotnik S
    BMJ Open; 2020 Feb; 10(2):e034356. PubMed ID: 32029494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD; Baker JF; Ogdie A
    J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry.
    Sørensen J; Hetland ML;
    Ann Rheum Dis; 2015 Mar; 74(3):e12. PubMed ID: 24534758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between depression, anxiety, chronic pain, or opioid use and tumor necrosis factor inhibitor persistence in inflammatory arthritis.
    Katz G; Ogdie A; Baker JF; George MD
    Clin Rheumatol; 2022 May; 41(5):1323-1331. PubMed ID: 35084601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study.
    Cordtz RL; Askling J; Delcoigne B; Smedby KE; Baecklund E; Ballegaard C; Isomäki P; Aaltonen K; Gudbjornsson B; Love TJ; Provan SA; Michelsen B; Sexton J; Dreyer L; Hellgren K
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36564101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
    Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
    Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
    Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
    Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study.
    Bengtsson K; Forsblad-d'Elia H; Lie E; Klingberg E; Dehlin M; Exarchou S; Lindström U; Askling J; Jacobsson LTH
    Arthritis Res Ther; 2017 May; 19(1):102. PubMed ID: 28521824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
    Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
    Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.